Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11117888
Irreversible inhibitors of pyruvate kinase M2 and the use thereof
granted -
US 11117899
[1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor
granted -
US 11117900
Compounds useful as inhibitors of ATR kinase
granted -
US 11117904
Compositions and methods for the delivery of therapeutics
granted -
US 11117972
Multivalent and multispecific OX40-binding fusion proteins
granted -
US 11117955
Anti-Zika virus antibodies and methods of use
granted -
US 11117968
Activatable anti-CTLA-4 antibodies and uses thereof
granted -
US 11117970
Human antibodies to PD-L1
granted -
US 11117973
Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms
granted -
US 11117975
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
granted -
US 11118167
Enzyme-mediated depletion of adenosine and/or methylthioadenosine
granted -
US 11118169
Compositions for increasing polypeptide stability and activity, and related methods
granted -
US 11118160
Probiotic composition for enhancing an insects resistance to a pesticide
granted -
US 11118177
Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
granted -
US 11118183
Modulation of angiopoietin-like 3 expression
granted -
US 11118186
Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer
granted -
US 11118192
Adeno-associated virus variant capsids and methods of use thereof
granted -
US 11118195
Universal donor cells
granted -
US 11118196
Universal donor cells
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
CA 3174918
OPICAPONE MICRONISEE
granted -
US 11123285
Auris formulations for treating OTIC diseases and conditions
granted -
US 11123286
Auris formulations for treating otic diseases and conditions
granted -
US 11123302
Formulation of acoustically activatable particles having low vaporization energy and methods for using same
granted -
US 11124537
Inhibitors of glucocorticoid receptor
granted -
US 11124489
EPAC antagonists
granted -
US 11123344
Bupropion as a modulator of drug activity
granted -
US 11123371
Restimulation of cryopreserved tumor infiltrating lymphocytes
granted -
US 11123312
Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
granted -
US 11123340
Small-molecule UT-A-selective urea transport inhibitors
granted -
US 11125741
Compositions and methods for the detection of zinc
granted -
US 11124839
Methods of treating cancer patients with farnesyltransferase inhibitors
granted -
US 11124805
Methods, compositions and kits for increasing genome editing efficiency
granted -
US 11124787
ADAMTS13-containing compositions having thrombolytic activity
granted -
US 11123283
Soluble estradiol capsule for vaginal insertion
granted -
US 11123357
Methods and compositions for treating oral mucositis
granted -
US 11123360
Oligonucleotides to treat eye disease
granted -
US 11122832
Methods and compositions to improve weight loss and cardiometabolic health beyond diet and excercise
granted -
US 11123441
Methods and compositions for drug delivery
granted -
US 11124835
Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
granted -
US 11123295
Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections
granted -
US 11123311
Methods of treating mental disorders
granted -
US 11123334
Compositions and methods for treating opioid overdose and opioid abuse
granted -
US 11123351
Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
granted -
US 11124901
Composite fabric, method for forming composite fabric, and use of a composite matter fabric
granted -
US 11124768
Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
granted -
US 11124567
Anti-TREM2 antibodies and methods of use thereof
granted -
US 11124550
Proteinaceous molecules and methods of use
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.